155 related articles for article (PubMed ID: 15005271)
1. Increase in peripheral blood flow by intravenous administration of prostaglandin E1 in patients with peripheral arterial disease, accompanied by up-regulation of hepatocyte growth factor.
Makino H; Aoki M; Hashiya N; Yamasaki K; Hiraoka K; Shimizu H; Azuma J; Kurinami H; Ogihara T; Morishita R
Hypertens Res; 2004 Feb; 27(2):85-91. PubMed ID: 15005271
[TBL] [Abstract][Full Text] [Related]
2. Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor.
Morishita R; Higaki J; Hayashi SI; Yo Y; Aoki M; Nakamura S; Moriguchi A; Matsushita H; Matsumoto K; Nakamura T; Ogihara T
Diabetologia; 1997 Sep; 40(9):1053-61. PubMed ID: 9300242
[TBL] [Abstract][Full Text] [Related]
3. Endothelial function in patients with peripheral vascular disease: influence of prostaglandin E1.
Weiss T; Fischer D; Hausmann D; Weiss C
Prostaglandins Leukot Essent Fatty Acids; 2002 Nov; 67(5):277-81. PubMed ID: 12445486
[TBL] [Abstract][Full Text] [Related]
4. Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease.
Matsui K; Ikeda U; Murakami Y; Yoshioka T; Shimada K
Am Heart J; 2003 Feb; 145(2):330-3. PubMed ID: 12595852
[TBL] [Abstract][Full Text] [Related]
5. Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes.
Morishita R; Nakamura S; Nakamura Y; Aoki M; Moriguchi A; Kida I; Yo Y; Matsumoto K; Nakamura T; Higaki J; Ogihara T
Diabetes; 1997 Jan; 46(1):138-42. PubMed ID: 8971094
[TBL] [Abstract][Full Text] [Related]
6. Effects of intravenous prostaglandin E1 on arterial compliance: a randomized controlled trial.
Mlekusch W; Schillinger M; Sabeti S; Al-Awami M; Gschwandtner M; Minar E
Vasa; 2004 Aug; 33(3):131-6. PubMed ID: 15461064
[TBL] [Abstract][Full Text] [Related]
7. Ocular and orbital blood flow velocity in patients with peripheral vascular disease and diabetes treated with intravenous prostaglandin E1.
Steigerwalt RD; Belcaro GV; Christopoulos V; Incandela L; Cesarone MR; De Sanctis MT
J Ocul Pharmacol Ther; 2001 Dec; 17(6):529-35. PubMed ID: 11777176
[TBL] [Abstract][Full Text] [Related]
8. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells.
Hayashi S; Morishita R; Nakamura S; Yamamoto K; Moriguchi A; Nagano T; Taiji M; Noguchi H; Matsumoto K; Nakamura T; Higaki J; Ogihara T
Circulation; 1999 Nov; 100(19 Suppl):II301-8. PubMed ID: 10567320
[TBL] [Abstract][Full Text] [Related]
9. Impaired endothelial dysfunction in diabetes mellitus rats was restored by oral administration of prostaglandin I2 analogue.
Matsumoto K; Morishita R; Tomita N; Moriguchi A; Yamasaki K; Aoki M; Matsumoto K; Nakamura T; Higaki J; Ogihara T
J Endocrinol; 2002 Oct; 175(1):217-23. PubMed ID: 12379506
[TBL] [Abstract][Full Text] [Related]
10. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
Böger RH; Bode-Böger SM; Thiele W; Creutzig A; Alexander K; Frölich JC
J Am Coll Cardiol; 1998 Nov; 32(5):1336-44. PubMed ID: 9809945
[TBL] [Abstract][Full Text] [Related]
11. Negative regulation of local hepatocyte growth factor expression by angiotensin II and transforming growth factor-beta in blood vessels: potential role of HGF in cardiovascular disease.
Nakano N; Morishita R; Moriguchi A; Nakamura Y; Hayashi SI; Aoki M; Kida I; Matsumoto K; Nakamura T; Higaki J; Ogihara T
Hypertension; 1998 Sep; 32(3):444-51. PubMed ID: 9740609
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandin E1 in peripheral vascular disease: a PET study of muscular blood flow.
Schellong SM; Burchert W; Böger RM; Creutzig A; Hundeshagen H; Alexander K
Scand J Clin Lab Invest; 1998 Apr; 58(2):109-17. PubMed ID: 9587162
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study.
Altstaedt HO; Berzewski B; Breddin HK; Brockhaus W; Bruhn HD; Cachovan M; Diehm C; Dörrler J; Franke CS; Gruss JD
Prostaglandins Leukot Essent Fatty Acids; 1993 Aug; 49(2):573-8. PubMed ID: 7692455
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy.
Morishita R; Nakamura S; Hayashi S; Taniyama Y; Moriguchi A; Nagano T; Taiji M; Noguchi H; Takeshita S; Matsumoto K; Nakamura T; Higaki J; Ogihara T
Hypertension; 1999 Jun; 33(6):1379-84. PubMed ID: 10373220
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of anti-ischemic action of prostaglandin E1 in peripheral arterial occlusive disease.
Schrör K; Hohlfeld T
Vasa; 2004 Aug; 33(3):119-24. PubMed ID: 15461062
[TBL] [Abstract][Full Text] [Related]
16. Effects of prostaglandin E1 infusion on limb hemodynamics and vasodilatory response in patients with arteriosclerosis obliterans.
Makita S; Nakamura M; Ohhira A; Itoh S; Hiramori K
Cardiovasc Drugs Ther; 1997 Jul; 11(3):441-8. PubMed ID: 9310272
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model.
Aoki M; Morishita R; Hayashi S; Jo N; Matsumoto K; Nakamura T; Kaneda Y; Ogihara T
Diabetologia; 2001 Aug; 44(8):1034-42. PubMed ID: 11484082
[TBL] [Abstract][Full Text] [Related]
18. [Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases].
Weiss T
Vasa; 2003 Nov; 32(4):187-92. PubMed ID: 14694766
[TBL] [Abstract][Full Text] [Related]
19. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure.
Nakamura Y; Morishita R; Nakamura S; Aoki M; Moriguchi A; Matsumoto K; Nakamura T; Higaki J; Ogihara T
Hypertension; 1996 Sep; 28(3):409-13. PubMed ID: 8794825
[TBL] [Abstract][Full Text] [Related]
20. Prostaglandin E1 increases the blood flow rate of saphenous vein grafts in patients undergoing off-pump coronary artery bypass grafting.
Zhao L; Lu J; Wang C; Zhao W; Qing E; Ma J
J Cardiothorac Vasc Anesth; 2013 Dec; 27(6):1208-11. PubMed ID: 24090805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
